Gilead Sciences, Inc. (GILD) earnings on May 7, 2026
More Gilead Sciences, Inc. earnings
Prior outlook: Pessimistic Outcome: Accurate
The stock price fell after the earnings announcement, continuing a prior trend of weakness. Investors reacted negatively to the news.
GILD price around the earnings
130.88
Change: -2.4%
2026-05-08, 23:43 UTC
Start of the measured window
End of the measured window
129.81
131.41
133.01
134.61
134.06
May 7, 2026
May 8, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Accurate
- Thesis published
100% beat history + analyst buy but -13.23% RS vs SPY — severe weakness.
100% beat history + analyst buy but -13.23% RS vs SPY — severe weakness.
Context analyzed before publication
- Summary
- Strong recent record of beating estimates + analyst buy rating but -13.23% RS vs SPY — severe weakness.
- Reasoning
- Strong recent record of beating estimates + analyst buy rating but -13.23% RS vs SPY — severe weakness.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.7
- Analysts covering the stock
- 28
- Average price target
- 158.36
- Lowest price target
- 123
- Highest price target
- 180
- Upside to price target
- 17.9%
- Quarterly earnings growth
- 22.4%
- Revenue growth
- 4.7%
- Forward EPS
- 9.62
- Trailing EPS
- 6.77
- Analyst moves in the last 60 days
- 3
- Strong buy: 5
- Buy: 17
- Hold: 8
- Sell: 0
- Strong sell: 0
- Strong buy
- 5
- Buy
- 17
- Hold
- 8
- Sell
- 0
- Strong sell
- 0
- April 13, 2026 · Citigroup: Maintains rating (Buy → Buy)
- April 10, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- March 10, 2026 · Jefferies: Initiates coverage (Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (7)
- Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call — Benzinga
- $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today — Benzinga
- Gilead Sciences Announces FDA New Drug Application Acceptance For Daily Oral HIV Treatment BIC/LEN — Benzinga
- What's Going On With Arcus Biosciences Stock On Wednesday? — Benzinga
- Gilead Sciences Receives All Required Regulatory Approvals To Acquire Arcellx At $115/Share — Benzinga
- Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today — Benzinga
- Gilead, U.S. State Department, PEPFAR And Global Fund Expand Lenacapavir Access To People For HIV Prevention Across High-Incidence Countries Through 2028 — Benzinga
Technicals
Evidence
- Average true range (ATR)
- 2%
- Distance to 52-week high
- -14.6%
- 14-day change (14d)
- -1.2%
- 30-day change
- -1.9%
- 30-day relative strength
- -13.2%
- Benchmark change
- +11.3%
- Nearest support
- 127.64
- Nearest resistance
- 142.94
- Volume accumulation ratio
- 1.13
Trends
Evidence
- Average earnings surprise
- +6.4%
- February 10, 2026: actual EPS 1.86 vs estimate 1.81 (surprise +2.8%)
- October 30, 2025: actual EPS 2.47 vs estimate 2.14 (surprise +15.7%)
- August 7, 2025: actual EPS 1.56 vs estimate 1.48 (surprise +5.1%)
- April 24, 2025: actual EPS 1.81 vs estimate 1.78 (surprise +1.9%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 3.9%
- 75th percentile move
- 5.1%
- 90th percentile move
- 7.6%
- Up / down moves
- 10 / 9
- Average up move
- +5.5%
- Average down move
- -3.1%
Monitoring and close
What Gilead Sciences, Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- -2.0%
- Max favorable move (MFE)
- 3.6%
- Max adverse move (MAE)
- 0.2%